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Introduction {#pds4167-sec-0006}
============

Cilostazol is a platelet aggregation inhibitor approved in Europe in 2002 to improve walking distances in patients with intermittent claudication. Cilostazol has been associated with spontaneous reports of cardiovascular adverse effects (heart attacks, angina, and arrhythmias) and serious bleeding. The European Medicines Agency (EMA) evaluated the benefits and risks of cilostazol in a referral and recommended labeling changes to include contraindications to patients with unstable angina pectoris, recent myocardial infarction, or recent coronary intervention (Table [1](#pds4167-tbl-0001){ref-type="table-wrap"}).[1](#pds4167-bib-0001){ref-type="ref"} The EMA also required a drug utilization study to support the benefit--risk evaluation of cilostazol before the implementation of labeling changes, which were introduced in 2013.

###### 

Changes to the cilostazol summary of product characteristics, 2013

  Indication                                                                                              Second‐line use after lifestyle modifications, including smoking cessation and (supervised) exercise programmes, failed to sufficiently improve symptoms.
  ------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Contraindications                                                                                       Unstable angina pectoris, myocardial infarction within the last 6 months, or a coronary intervention in the last 6 months
  Concomitant treatment with two or more additional antiplatelet agents (e.g., aspirin and clopidogrel)   
  Warnings and precautions                                                                                Close monitoring of patients at increased risk for serious cardiac adverse events as a result of increased heart rate, for example, patients with stable coronary disease or a history of tachyarrhythmias
  Posology                                                                                                Reduction of the dose to 50 mg twice daily in patients receiving medicines that strongly inhibit CYP3A4 or CYP2C19

We present results of the drug utilization study conducted in the UK, Spain, Sweden, and Germany by using information from automated health databases. The main objectives were to describe the characteristics of new users of cilostazol, including comorbidity and comedications, to assess potential off‐label prescribing and conduct a baseline assessment of the labeling changes recommended by the EMA.

Methods {#pds4167-sec-0007}
=======

Data sources {#pds4167-sec-0008}
------------

New users of cilostazol were identified in five databases: The Health Improvement Network (THIN), UK[2](#pds4167-bib-0002){ref-type="ref"}, [3](#pds4167-bib-0003){ref-type="ref"}, [4](#pds4167-bib-0004){ref-type="ref"}; the EpiChron cohort from Aragon Health Sciences Institute, Aragon, Spain; the Information System for the Improvement of Research in Primary Care (SIDIAP), Catalonia, Spain[5](#pds4167-bib-0005){ref-type="ref"}; the Swedish National Registers[6](#pds4167-bib-0006){ref-type="ref"}, [7](#pds4167-bib-0007){ref-type="ref"}; and the German Pharmacoepidemiological Research Database (GePaRD).[8](#pds4167-bib-0008){ref-type="ref"} Main characteristics of the study databases are presented in Table S1.

Study population {#pds4167-sec-0009}
----------------

The study included all new users of cilostazol identified in the study databases because the date cilostazol was available in each country before the implementation in 2013 of labeling changes requested by the EMA. New users were defined as patients who received a first‐ever prescription of cilostazol during the study period and had at least 6 months of continuous enrollment in the study databases before this first prescription (start date). New users were followed from the start date until the earliest of end of enrollment in the database, death, or end of the study period.

Exposure definition {#pds4167-sec-0010}
-------------------

We defined exposure to cilostazol as the number of days\' supply calculated from the quantity prescribed and dosage instructions or from a descriptive analysis of the time between consecutive prescriptions. An interval of 7 days was added to days\' supply to allow for delay in the start of treatment and incomplete adherence. Continuous use of cilostazol was defined as the total number of days covered by consecutive prescriptions, with a maximum gap of 60 days between the end of days\' supply of one prescription and the start of the next prescription. In THIN and the EpiChron cohort, daily dose was calculated from strength of product, package quantity, and dosage instructions. In the EpiChron cohort, daily dose information was available for 1052 patients (26.1%). In Sweden and GePaRD, daily dose was calculated by assuming a twice‐daily dosage. In SIDIAP, evaluation of daily dose was not conducted as information on dosage instructions was not available.

Characterization of users {#pds4167-sec-0011}
-------------------------

New users of cilostazol were characterized at the start date according to age, sex, socioeconomic status, comorbidity and comedications, concurrent use of interacting medications, and contraindications before and after the EMA‐requested labeling changes.

Interacting medications evaluated were those interacting with cytochrome P‐450 (CYP) enzymes, particularly CYP3A4 and CYP2C19, including potent CYP3A4 and CYP2C19 inhibitors.[9](#pds4167-bib-0009){ref-type="ref"}, [10](#pds4167-bib-0010){ref-type="ref"}

Old cilostazol contraindications evaluated were severe renal impairment, moderate‐to‐severe hepatic impairment, congestive heart failure, predisposing factors for bleeding (active peptic ulcer, hemorrhagic stroke within the prior 6 months, proliferative diabetic retinopathy, and poorly controlled hypertension), and history of specific arrhythmia.

Baseline assessment of labeling changes {#pds4167-sec-0012}
---------------------------------------

To assess the potential impact of the cilostazol labeling changes, we conducted a baseline assessment of the frequency of conditions included in the labeling recommended by the EMA (Table [1](#pds4167-tbl-0001){ref-type="table-wrap"}). Information on smoking was available in THIN, the EpiChron cohort, and SIDIAP. In Sweden, we evaluated smoking by using diagnosis codes for smoking‐related disease and use of smoking‐cessation drugs. Information on smoking was not available in GePaRD. Monitoring of patients after 3 months was assessed by the number of patients who had at least one visit to a general practitioner (GP) or specialist (vascular surgery, cardiology, and diabetology) 2--4 months after the start date. In Sweden, evaluation of visits was restricted to the hospital setting. In GePaRD, diagnoses are recorded on a quarterly basis and visits were evaluated by the number of patients who had at least one diagnosis for intermittent claudication recorded in the 3 months following the quarter in which cilostazol was started. In THIN and SIDIAP, the reason for visits to GPs and specialists was assessed by clinically reviewing computerized information and free text for a random sample of 200 patients. Discontinuation of cilostazol after 3 months was evaluated for the first period of continuous use. New contraindications included in the revised label approved by the EMA were unstable angina pectoris, myocardial infarction or coronary intervention within 6 months before the start date, and concurrent use of cilostazol and two or more additional platelet aggregation inhibitors. Monitoring of patients at increased risk of serious cardiac events was evaluated by comparing rates of visits to GPs or specialists between patients with and without a history of arrhythmias, hypotension, or coronary heart disease. In GePaRD, monitoring was expressed as the number of diagnoses per patient‐year of continuous use because only the first visit to the same physician is recorded during a quarter.

Potential off‐label prescribing {#pds4167-sec-0013}
-------------------------------

In THIN and SIDIAP, potential off‐label prescribing was evaluated through manual review of computerized clinical information and free text of a random sample of 200 patients. In other databases, indication was evaluated by using diagnostic codes and referrals. On‐label prescribing was defined as any patient who had a recorded diagnosis of intermittent claudication or peripheral arterial disease recorded at any time before or after the start date or who had a referral to vascular surgery, cardiology, or diabetology within 1 month before and 1 month after the start date (28 days were used in Germany). In Germany, the period of ascertainment of diagnoses was the calendar quarter before and after the start date.

Analysis {#pds4167-sec-0014}
--------

The average annual prevalence of cilostazol use was calculated by using the age and sex distribution of the population in each database. The cumulative proportion of patients discontinuing cilostazol was calculated by using survival analysis. Rates of visits were calculated as the number of visits per 100 person‐years of continuous use of cilostazol, except in GePaRD, where the number of diagnoses per patient‐year was used. Crude incidence rate ratios and 95% confidence intervals were estimated to compare rates of visits between patients at high risk of cardiac complications and patients not at high risk.

At RTI Health Solutions (RTI‐HS; THIN data), SIDIAP, Sweden, and GePaRD, analyses were conducted by using [sas]{.smallcaps} version 9.3 or 9.4 (Cary, NC: SAS Institute Inc.). [stata]{.smallcaps} v13.0 (StataCorp, 2013) was used in the EpiChron cohort. [stata]{.smallcaps} v13.1 and R 3.1 (R Core Team, 2013) were also used in SIDIAP.

The protocol was approved by the EMA and posted in the EU PAS Register in March 2013 (EU PAS ID 3596).[11](#pds4167-bib-0011){ref-type="ref"}

Results {#pds4167-sec-0015}
=======

Prevalence and patterns of use {#pds4167-sec-0016}
------------------------------

We included 22 593 new users of cilostazol. SIDIAP (Spain) contributed the largest proportion of users (44.9%; Table [2](#pds4167-tbl-0002){ref-type="table-wrap"}). The average annual prevalence of cilostazol use was higher in Spain than in the other countries. Between 52.3% (Sweden) and 77.3% (SIDIAP) of users were men. The median age ranged from 68.0 years in SIDIAP to 73.7 years in Sweden and was higher in women than in men in all study populations.

###### 

Study period, number of new users, age and sex distribution, and patterns of use of cilostazol

  Characteristic                                   THIN, UK                   EpiChron Cohort, Aragon, Spain              SIDIAP, Catalonia, Spain                      Sweden                                             GePaRD, Germany
  ------------------------------------------------ -------------------------- ------------------------------------------- --------------------------------------------- -------------------------------------------------- -------------------------
  Study period                                     29 Jul 2002--14 Sep 2012   1 Jun 2009--31 Dec 2012                     1 Jun 2009--31 Dec 2012                       1 Jan 2008--31 Dec 2012                            1 Jan 2007--31 Dec 2011
  Number of users                                  1528                       4024                                        10 142                                        2887                                               4012
  Average annual prevalence of use (per 100 000)   8.9                        162.4                                       133.5                                         13.3                                               17.0
  Men                                              65.6%                      72.2%                                       77.3%                                         52.3%                                              73.3%
  Median age (years)                                                                                                                                                                                                       
  Men                                              68.0                       69.0                                        68.0                                          72.4                                               67.8
  Women                                            71.0                       73.9                                        75.0                                          75.0                                               68.7
  Total number of prescriptions                    21 513                     35 719                                      47 205                                        11 295                                             23 478
  Total number of DDDs                             715 716                    1 133 944                                   3 738 812                                     613 897                                            982 846
  Total number of prescriptions per user                                                                                                                                                                                   
  1                                                28.6%                      31.1%                                       15.9%                                         42.0%                                              32.9%
  2--4                                             22.8%                      20.4%                                       18.9%                                         29.2%                                              28.9%
  5+                                               48.6%                      48.5%                                       65.2%                                         28.8%                                              38.2%
  Number of users of 50‐mg strength                25.8%                      NA[\*](#pds4167-note-0014){ref-type="fn"}   NA[\*](#pds4167-note-0014){ref-type="fn"}     23.4%                                              14.5%
  Number of users of 10‐mg strength                82.1%                      100%                                        100%                                          81.0%                                              91.7%
  Daily dose of 200 mg at start date               85.7%                      77.3%                                       NA[\*\*](#pds4167-note-0015){ref-type="fn"}   78.1%                                              87.9%
  Discontinuation of use                                                                                                                                                                                                   
  \<1 month                                        28.7%                      33.9%                                       22.2%                                         38.2%[\*\*\*](#pds4167-note-0016){ref-type="fn"}   --
  \<3 months                                       52.9%                      51.9%                                       40.6%                                         39.4%                                              51.9%
  \<6 months                                       62.2%                      60.5%                                       50.4%                                         65.2%                                              64.9%
  \<12 months                                      71.3%                      69.1%                                       64.6%                                         81.9%                                              77.8%
  \<24 months                                      79.8%                      77.8%                                       82.0%                                         92.1%                                              87.5%

GePaRD, German Pharmacoepidemiological Research Database, Germany; EpiChron, EpiChron cohort from Aragon Health Sciences Institute (IACS), Aragón, Spain; SIDIAP, Information System for the Improvement of Research in Primary Care, Catalonia, Spain; THIN, The Health Improvement Network, UK; UK, United Kingdom.

Strength of 50 mg was not available in Spain.

Information on daily dose not available in SIDIAP.

Refers to first 2 months of treatment.

From 15.9% (SIDIAP) to 42.0% (Sweden) of users received only one prescription. Most users received a daily dose of 200 mg at the start date. The percentage of users discontinuing cilostazol in the first 6 months of treatment ranged from 50.4% in SIDIAP to 65.2% in Sweden. Information on socioeconomic status of new users of cilostazol is presented in Table S2.

Baseline comorbidity {#pds4167-sec-0017}
--------------------

Cardiovascular disease other than peripheral vascular disease was the most frequent comorbidity in all study populations, affecting 62.8% (Sweden) to 95.7% (GePaRD) of users (Table [3](#pds4167-tbl-0003){ref-type="table-wrap"}). The most frequent cardiovascular condition was hypertension, ranging from 46.8% (Sweden) to 86.0% of users (GePaRD). Between 20.4% (Sweden) and 75.3% (GePaRD) of users had a recorded diagnosis of hyperlipidemia, and 20.5% (Sweden) to 41.1% (GePaRD) had a diagnosis of diabetes. Use of comedications at the start date was consistent with the prevalence of comorbidity (Table S3). The most frequent comedications were antihypertensive drugs (63.6 to 80.6% of users), platelet aggregation inhibitors (33.8 to 73.1%), lipid‐modifying agents (45.8 to 68.6%), and proton pump inhibitors (22.4 to 60.9%).

###### 

Comorbidity among new users of cilostazol[\*](#pds4167-note-0006){ref-type="fn"}

  Disease description                                                                   THIN, UK  EpiChron Cohort, Aragon, Spain    SIDIAP, Catalonia, Spain  Sweden    GePaRD, Germany                              
  ------------------------------------------------------------------------------------ ---------- -------------------------------- -------------------------- -------- ----------------- ------ ------ ------ ------ ------
  Cardiovascular diseases and procedures                                                  1399    91.6                                        3251            80.8           9027        89.0    2290  79.3    3972  99.0
  Diseases of arteries, arterioles, and capillaries                                       1101    72.1                                        1453            36.1           5097        50.3    1605  55.6    3690  92.0
  Intermittent claudication                                                               808     52.9                                        1453            36.1           4268        42.1    1043  36.1    3151  78.5
  Other peripheral arterial disease                                                       652     42.7                                        1453            36.1            499        4.9     1003  34.7    3149  78.5
  Revascularization procedures                                                            164     10.7                                         0              0.0              4         0.0     525   18.2    1349  33.6
  Cardiovascular disease excluding diseases of arteries, arterioles, and capillaries      1157    75.7                                        2997            74.5           8338        82.2    1812  62.8    3838  95.7
  Ischemic heart disease                                                                  497     32.5                                        563             14.0           1746        17.2    912   31.6    2111  52.6
  Acute myocardial infarction                                                             194     12.7                                        274             6.8             674        6.6     399   13.8    631   15.7
  Unstable angina pectoris                                                                 60     3.9                                         229             5.7             114        1.1     264   9.1     408   10.2
  Angina pectoris                                                                         301     19.7                                        229             5.7             161        1.6     609   21.1    750   18.7
  Coronary reperfusion and procedures                                                     189     12.4                                         0              0.0             48         0.5     531   18.4    518   12.9
  Arrhythmias                                                                             138     9.0                                         157             3.9             629        6.2     338   11.7    1199  29.9
  Paroxysmal tachycardia                                                                   6      0.4                                          9              0.2             47         0.5      47   1.6     167   4.2
  Atrial fibrillation and flutter                                                          97     6.3                                         133             3.3             475        4.7     260   9.0     535   13.3
  Heart failure                                                                            73     4.8                                         118             2.9             406        4.0     266   9.2     983   24.5
  Cerebrovascular disease                                                                 189     12.4                                        313             7.8             971        9.6     339   11.7    1815  45.2
  Hypertension                                                                            825     54.0                                        2209            54.9           6388        63.0    1352  46.8    3451  86.0
  Hypotension                                                                              37     2.4                                          14             0.4             27         0.3      25   0.9     264   6.6
  Disorders of lipoprotein metabolism                                                     478     31.3                                        1503            37.4           4915        48.5    589   20.4    3021  75.3
  Bleeding disorders                                                                      346     22.6                                        160             4.0             568        5.6     338   11.7    1120  27.9
  Cerebral hemorrhage                                                                      8      0.5                                          0              0.0             30         0.3      20   0.7      62   1.5
  Gastrointestinal bleeding                                                               169     11.1                                         44             1.1             230        2.3     142   4.9     504   12.6
  Gastroduodenal bleeding                                                                  61     4.0                                          18             0.5             94         0.9     102   3.5     299   7.5
  Lower gastrointestinal bleeding                                                         114     7.5                                          26             0.7             135        1.3      38   1.3     190   4.7
  Genitourinary                                                                           133     8.7                                          87             2.2             213        2.1     122   4.2     451   11.2
  Other site                                                                               90     5.9                                          33             0.8             152        1.5      77   2.7     276   6.9
  Blood dyscrasias                                                                         97     6.3                                         203             5.0             378        3.7     162   5.6     923   23.0
  Peptic ulcer disease                                                                    136     8.9                                          83             2.1             549        5.4     101   3.5     354   8.8
  Liver disease                                                                            20     1.3                                          63             1.6             396        3.9      30   1.0     1021  25.4
  Renal failure                                                                            37     2.4                                          0              0.0             830        8.2      80   2.8     830   20.7
  Skin disorders                                                                          399     26.1                                        641             15.9            882        8.7     225   7.8     1691  42.1
  Diabetes mellitus                                                                       326     21.3                                        1201            29.9           4102        40.4    593   20.5    1648  41.1
  Chronic obstructive pulmonary disease                                                   194     12.7                                        694             17.3           1823        18.0    247   8.6     1727  43.0
  Asthma                                                                                  215     14.1                                        115             2.9             206        2.0     106   3.7     395   9.8
  Rheumatoid arthritis                                                                     30     2.0                                         198             4.9             666        6.6     144   5.0     921   23.0
  Malignancy                                                                              197     12.9                                        316             7.9            1107        10.9    481   16.7    1002  25.0

COPD, chronic obstructive pulmonary disease; GePaRD, German Pharmacoepidemiological Research Database, Germany; GP, general practitioner; EpiChron, EpiChron cohort from Aragon Health Sciences Institute (IACS), Aragón, Spain; NA, not available; SIDIAP, Information System for the Improvement of Research in Primary Care, Catalonia, Spain; THIN, The Health Improvement Network, UK; UK, United Kingdom.

Comorbidity was evaluated for any time before the start date.

Concurrent use of interacting medications {#pds4167-sec-0018}
-----------------------------------------

Between 78.8% (GePaRD) and 91.6% (THIN) of users were concurrently treated with interacting medications (Table S4). The most frequent interacting medications were simvastatin, atorvastatin, amlodipine, omeprazole, and clopidogrel. The percentages of users treated with potent CYP3A4 or CYP2C19 inhibitors were 2.7% (Sweden), 3.8% (GePaRD), 7.3% (SIDIAP), 10.2% (EpiChron cohort), and 22.3% (THIN). Between 26.9% (GePaRD) and 69.0% (THIN) of users were concurrently treated with other platelet aggregation inhibitors. Among these users, 8.5% (SIDIAP) to 21.1% (GePaRD) discontinued platelet aggregation inhibitors after starting cilostazol.

Assessment of contraindications {#pds4167-sec-0019}
-------------------------------

The percentages of users with diagnoses suggestive of contraindications included in the label before the 2013 changes were 6.2% (EpiChron cohort), 10.0% (THIN), 12.2% (Sweden), 39.1% (SIDIAP), and 51.8% (GePaRD; Table [4](#pds4167-tbl-0004){ref-type="table-wrap"}). The prevalence of each individual contraindication, except heart failure, was higher in GePaRD than in other study populations. SIDIAP was the only database in which poorly controlled hypertension could be evaluated.

###### 

Percentage of new users of cilostazol with old contraindications

  Contraindication[\*](#pds4167-note-0009){ref-type="fn"}                       THIN, UK (*n* = 1528)   EpiChron Cohort, Aragon, Spain (*n* = 4024)   SIDIAP, Catalonia, Spain (*n* = 10 142)   Sweden (*n* = 2887)   GePaRD, Germany (*n* = 4012)
  ----------------------------------------------------------------------------- ----------------------- --------------------------------------------- ----------------------------------------- --------------------- ------------------------------
  Renal failure                                                                 2.4                     NA                                            7.9                                       2.8                   20.7
  Liver disease                                                                 1.3                     1.6                                           3.7                                       1.0                   25.4
  Heart failure                                                                 4.8                     2.9                                           3.7                                       3.0                   3.9
  Risk factors for bleeding                                                     1.8                     1.7                                           29.9                                      5.7                   16.3
  Active peptic ulcer                                                           0.1                     0.1                                           0.1                                       0.4                   3.9
  Recent cerebral hemorrhage                                                    0.0                     NA                                            0.2                                       0.1                   0.6
  Proliferative diabetic retinopathy[\*\*](#pds4167-note-0010){ref-type="fn"}   0.7                     1.7                                           4.5                                       5.2                   12.4
  Poorly controlled hypertension[\*\*\*](#pds4167-note-0011){ref-type="fn"}     1.0                     NA                                            26.6                                      NA                    NA
  Arrhythmias                                                                   0.7                     0.2                                           0.03                                      1.4                   8.3
  Ventricular tachycardia                                                       0.1                     0.2                                           0.02                                      0.6                   1.5
  Ventricular fibrillation or multifocal ventricular ectopics                   0.5                     NA                                            0.01                                      0.8                   7.3
  Prolongation of the QT interval                                               0.0                     NA                                            NA                                        0.1                   NA
  Any contraindication                                                          10.0                    6.2                                           39.1                                      12.2                  51.8

GePaRD, German Pharmacoepidemiological Research Database, Germany; EpiChron, EpiChron cohort from Aragon Health Sciences Institute (IACS), Aragón, Spain; NA, not available; SIDIAP, Information System for the Improvement of Research in Primary Care, Catalonia, Spain; THIN, The Health Improvement Network, UK; UK, United Kingdom.

Note: Old contraindications refer to those already included in the labeling before the implementation of labeling changes in 2013.

Contraindications were severe renal impairment, moderate‐to‐severe hepatic impairment, congestive heart failure, risk factors for bleeding (active peptic ulcer, hemorrhagic stroke within the prior 6 months, proliferative diabetic retinopathy, and poorly controlled hypertension), and history of arrhythmias.

Refers to diabetic retinopathy.

Poorly controlled hypertension was evaluated in THIN by using specific Read codes and in SIDIAP defined as any patient with a blood pressure value greater than 140/90 mmHg or diagnosed with hypertension without at least one control of blood pressure recorded in the last 12 months. Blood pressure values were not available in the rest of the study populations.

Baseline assessment of labeling changes {#pds4167-sec-0020}
---------------------------------------

The baseline assessment of labeling changes is presented in Table [5](#pds4167-tbl-0005){ref-type="table-wrap"}. For databases with information from GPs, current smoking at the start date was found in 15.9% of users (EpiChron cohort), 30.4% (THIN), and 32.3% (SIDIAP). In these populations, 80.9--83.6% of users had a visit with a GP or specialist 2--4 months after starting cilostazol. Discontinuation within the first 3 months ranged from 39.4% (Sweden) to 52.9% (THIN) of users. Between 1.5% (THIN) and 11.6% (GePaRD) of users had new cardiovascular contraindications at the start date, and 6.3% (SIDIAP) to 13.5% (EpiChron cohort) were concurrently treated with two or more additional platelet aggregation inhibitors. In all databases, rates of visits with GPs or specialists were higher in users with increased risk of serious cardiovascular events than in users without such risk. Between 2.1% (Sweden) and 19.6% (THIN) of users had concurrent use of cilostazol 200 mg per day and potent CYP3A4 or CYP2C19 inhibitors. Among patients treated with a daily dose of 200 mg who started potent inhibitors during follow‐up (*n* = 235), reduction of the cilostazol daily dose was found in one patient.

###### 

Baseline assessment of cilostazol labeling changes

  Labeling changes                                                                                                                                         Study variable                                                                                                              THIN, UK (*n* = 1528)                              EpiChron cohort, Aragon, Spain (*n* = 4024)   SIDIAP, Catalonia, Spain (*n* = 10 142)            Sweden (*n* = 2887)                                                  GePaRD, Germany (*n* = 4012)
  -------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------- --------------------------------------------- -------------------------------------------------- ------------------------------------------------------ ---------------------------------------------------------
  Indication                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Smoking cessation                                                                                                                                        Current smoking at the start date                                                                                           30.4%                                              15.9%                                         32.3%                                              3.2%[\*](#pds4167-note-0014){ref-type="fn"}                                       NA
  Physician reassessment of patients after 3 months                                                                                                        Visit to GP or specialist[\*\*](#pds4167-note-0010){ref-type="fn"} between 2 and 4 months after the start date              80.9%[\*\*\*](#pds4167-note-0011){ref-type="fn"}   83.6%                                         82.0%[\*\*\*](#pds4167-note-0011){ref-type="fn"}   8.6%[†](#pds4167-note-0017){ref-type="fn"}                                        NA
                                                                                                                                                           Visit related to intermittent claudication                                                                                  49.6%[\*\*\*](#pds4167-note-0011){ref-type="fn"}   21.3%                                         53.5%[\*\*\*](#pds4167-note-0011){ref-type="fn"}   8.5%[†](#pds4167-note-0017){ref-type="fn"}                                       62.2%
                                                                                                                                                           Discontinuation before 3 months of treatment                                                                                52.9%                                              51.9%                                         40.6%                                              39.4%                                                                            51.9%
  Contraindications                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Unstable angina pectoris, myocardial infarction,[‡](#pds4167-note-0018){ref-type="fn"} and coronary intervention[‡](#pds4167-note-0018){ref-type="fn"}   Recorded diagnosis codes for contraindications                                                                              1.5%                                               1.7%                                          3.0%                                               5.2%                                                                             11.6%
  Concomitant treatment with two or more additional platelet aggregation inhibitors                                                                        Recorded drug codes for platelet aggregation inhibitors                                                                     9.8%                                               13.5%                                         6.3%                                               8.4%                                                                             7.5%
  Warnings and precautions                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Close monitoring of patients at increased risk for serious cardiac adverse events[§](#pds4167-note-0019){ref-type="fn"}                                  Rate of visits to GP or specialist per 100 person‐years (95%CI)                                                                                                                                                                                                                                                                        
                                                                                                                                                           Rates (95%CI) in patients at increased risk                                                                                 1457 (1430--1485)                                  3390 (3348--3432)                             566 (556--575)                                     923 (901--944)[†](#pds4167-note-0017){ref-type="fn"}    2.75 (2.68--2.82)[¶](#pds4167-note-0020){ref-type="fn"}
                                                                                                                                                           Rates (95%CI) in patient not at increased risk                                                                              1354 (1335--1373)                                  3032 (3013--3052)                             475 (470--480)                                     485[†](#pds4167-note-0017){ref-type="fn"} (473--497)    2.66 (2.58--2.75)[¶](#pds4167-note-0020){ref-type="fn"}
                                                                                                                                                           Rate ratio increased/no increased risk (95%CI)                                                                              1.08 (1.05--1.10)                                  1.12 (1.10--1.13)                             1.19 (1.17--1.22)                                  1.90 (1.84--1.97)                                                          1.03 (0.99--1.08)
  Posology                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Reduction of daily dose to 100 mg in patients receiving medicines strongly interacting with CYP3A4 or CYP2C19 enzymes                                    Concurrent use of cilostazol 200 mg per day and CYP3A4 or CYP2C19 potent inhibitors[a](#pds4167-note-0021){ref-type="fn"}   19.6%                                              10.0%[b](#pds4167-note-0022){ref-type="fn"}   NA                                                 2.1%                                                                             3.4%
                                                                                                                                                           At the start date                                                                                                           9.9%                                               6.8%[b](#pds4167-note-0022){ref-type="fn"}    NA                                                 1.0%                                                                             1.5%
                                                                                                                                                           During follow‐up[c](#pds4167-note-0023){ref-type="fn"}                                                                      9.7%                                               3.1%[b](#pds4167-note-0022){ref-type="fn"}    NA                                                 1.1%                                                                             2.1%
                                                                                                                                                           Dose reduction after start of a CYP3A4 or CYP2C19 potent inhibitor[a](#pds4167-note-0021){ref-type="fn"} during follow‐up   0.0%                                               0.0%[b](#pds4167-note-0022){ref-type="fn"}    NA                                                 0.0%                                                                             1.2%

CI, confidence interval; GePaRD, German Pharmacoepidemiological Research Database, Germany; GP, general practitioner; EpiChron, EpiChron cohort from Aragon Health Sciences Institute (IACS), Aragón, Spain; NA, not available; RR, rate ratio; SIDIAP, Information System for the Improvement of Research in Primary Care, Catalonia, Spain; THIN, The Health Improvement Network, UK; UK, United Kingdom.

Note: baseline assessment refers to evaluation of labeling changes before they were implemented during 2013.

In Sweden, smoking at the start date was evaluated through smoking‐related diagnosis and dispensings for smoking‐cessation drugs only.

Specialties were vascular surgery, cardiology, or diabetology.

Based on the review of patient profiles and free text of a random sample of 200 users in THIN and 200 users in SIDIAP.

Hospital inpatient and outpatient visits. Information on GP visits was not available in Sweden.

Within the last 6 months.

Increased risk of serious cardiac events as a result of increased heart rate, for example, patients with stable coronary disease or a history of tachyarrhythmias.

Number of diagnoses per patient‐year during continuous use of cilostazol.

CYP3A4 or CYP2C19 potent inhibitors: lansoprazole, fluvoxamine, nefazodone, ticlopidine, clarithromycin, troleandomycin, indinavir, ritonavir, nelfinavir, mibefradil, ketoconazole, and itraconazole.

Based on 1052 (26.1%) patients with available information on daily dose.

Number of users treated with a daily dose of 200 mg who started potent inhibitors during follow‐up: 85 in THIN, 33 in the EpiChron cohort, 32 in Sweden, and 85 in Germany.

Off‐label prescribing {#pds4167-sec-0021}
---------------------

Between 41.0% (SIDIAP) and 93.4% (THIN) of users had a recorded diagnosis compatible with the labelled indication (Table [6](#pds4167-tbl-0006){ref-type="table-wrap"}). Potential off‐label prescribing ranged from 5.6% (THIN) to 24.5% (Sweden) of users. Between 1.0% (THIN) and 48.7% (SIDIAP) of users had recorded diagnoses not related to the potential on‐label use of cilostazol or did not have any recorded diagnosis around the start date. Potential off‐label cardiovascular indications of cilostazol were cerebrovascular disease (0.3%, EpiChron cohort and Sweden; 4.8%, GePaRD) and ischemic heart disease (0.3%, EpiChron cohort; 7.0%, GePaRD).

###### 

Potential off‐label prescribing of cilostazol

  Diagnosis                                    THIN, UK (*n* = 1528)[\*](#pds4167-note-0025){ref-type="fn"}   EpiChron Cohort, Aragon, Spain (*n* = 4024)      SIDIAP, Catalonia, Spain (*n* = 10 142)[\*](#pds4167-note-0025){ref-type="fn"}   Sweden (*n* = 2887)   GePaRD, Germany (*n* = 4012)
  -------------------------------------------- -------------------------------------------------------------- ------------------------------------------------ -------------------------------------------------------------------------------- --------------------- ------------------------------
  On‐label prescribing                         93.4%                                                          53.6%                                            41.0%                                                                            70.2%                 81.6%
  Potential off‐label prescribing              5.6%                                                           7.9%                                             10.3%                                                                            24.5%                 17.0%
  Varices, phlebitis, and thrombophlebitis     0.0%                                                           2.0%                                             2.1%                                                                             2.3%                  3.9%
  Leg and foot pain, symptoms, and complains   3.6%                                                           1.5%                                             2.1%                                                                             1.3%                  0%
  Musculoskeletal disorders                    0.0%                                                           1.2%                                             0.0%                                                                             3.7%                  4.6%
  Cerebrovascular disease                      1.0%                                                           0.3%                                             2.1%                                                                             0.3%                  4.8%
  Ischemic heart disease                       0.5%                                                           0.3%                                             1.0%                                                                             0.6%                  7.0%
  Other cardiovascular disease                 0.0%                                                           1.6%                                             0.0%                                                                             16.2%                 15.0%
  Peripheral neuritis and neuropathy           1.0%                                                           0.02%                                            0.0%                                                                             0.0%                  0.0%
  Other diagnoses/no diagnoses recorded        1.0%                                                           38.5%[\*\*](#pds4167-note-0015){ref-type="fn"}   48.7%[\*\*\*](#pds4167-note-0016){ref-type="fn"}                                 5.4%                  1.5%

GePaRD, German Pharmacoepidemiological Research Database, Germany; GP, general practitioner; EpiChron, EpiChron cohort from Aragon Health Sciences Institute (IACS), Aragón, Spain; SIDIAP, Information System for the Improvement of Research in Primary Care, Catalonia, Spain; THIN, The Health Improvement Network, UK; UK, United Kingdom.

Based on clinical review of patient profiles and free text of a random sample of users.

A total of 1541 patients (38.3%) had other diagnoses, and 11 (0.3%) did not have any recorded diagnosis.

A total of 14 patients (7.2%) had other diagnoses, and 81 (41.5%) did not have any recorded diagnosis.

Discussion {#pds4167-sec-0022}
==========

In this study, we described the characteristics of 22 593 new users of cilostazol identified in the UK, Spain, Sweden, and Germany. Prevalence of use varied across study populations and countries, and it was higher in Spain than in the other countries. Most users were aged older than 60 years and had a high prevalence of comorbidity, especially cardiovascular disease and use of comedications. Concurrent use of cilostazol and potent CYP3A4 and CYP2C19 inhibitors ranged from 3 to 22% of users. The baseline assessment of labeling changes enabled estimation of the potential impact that could be achieved after the labeling changes were implemented in 2013. Up to one third of users were current smokers when initiating treatment; most patients were monitored after the start of treatment, up to 50% discontinued cilostazol in the first 3 months of therapy; and prevalence of new contraindications and concurrent use of cilostazol 200 mg daily and potent CYP3A4 and CYP2C19 inhibitors was low. On‐label prescribing of cilostazol was variable, lower in Spain than in other countries, and variability was probably related to the extent to which diagnoses and free text were recorded in different databases.

Published information on cilostazol use in general practice is limited to a drug utilization study conducted in Spain by Cantabrian regional health service and the Spanish Medicines and Health Products Agency[12](#pds4167-bib-0012){ref-type="ref"}; the results are published only in an abstract. The results from the EpiChron cohort and SIDIAP (Spain) in our study are in line with results from this study: Most cilostazol users were elderly, with a high prevalence of comorbidity and comedications, including those potentially interacting with cilostazol, and did not achieve 6 months of treatment. The high rates of discontinuation found in that study and in our study could be driven not only by a potential lack of effectiveness of cilostazol but also by intolerance or adverse effects. Our study was not designed to assess cause of discontinuation, and the clinical information evaluated (e.g., reasons for monitoring visits) did not provide further insight. In a large randomized clinical trial, the most frequent reasons for early termination were patient withdrawal of consent (16%), adverse events (18%), and other reasons (10%) (Hiatt *et al*., 2008). The high prevalence of comorbidity and concurrent use of multiple medications, many interacting with cilostazol, could also reduce the adherence to cilostazol treatment. For example, the concurrent use of statins (41.8--66.8% of new users) could precipitate or aggravate leg pain, which could be attributed to lack of efficacy of cilostazol and lead to discontinuation of treatment.

A strength of our study is the use of automated health databases, which typically capture information from routine health care without modifying regular clinical practice. This allowed identification and characterization of long‐term baseline medication and comorbidity history of a large number of cilostazol new users in several European populations---all of Sweden and with good representation of the overall country populations for other countries. The availability of prescription and dispensing records allowed a detailed evaluation of coprescription patterns over long periods of time. A limitation of the use of databases is the heterogeneity of the data available for each population, which may explain part of the variability of the prevalence of comorbidity and contraindications (e.g., renal failure and liver disease) in the different study populations. The different health systems in each country or region also contribute to the heterogeneity between databases. Information recorded in THIN and GePaRD is based on primary care, specialists, and hospital discharge diagnoses. In the EpiChron cohort and SIDIAP, information was restricted to primary care diagnoses and in Sweden was limited to inpatient and outpatient clinic hospital diagnoses.

Availability and specificity of some diagnoses used to assess comorbidity and contraindications varied between databases. Specific codes for renal failure and cerebral hemorrhage were not available in the EpiChron cohort. The diagnosis of proliferative diabetic retinopathy was available in THIN only and was approximated in the other databases by using the broader term of diabetic retinopathy; poorly controlled hypertension was evaluated in SIDIAP through recorded values of blood pressure and in THIN through Read codes. Also, to assess contraindications associated with disease severity (e.g., moderate‐to‐severe hepatic impairment), which is not captured in the study databases, we used broad diagnostic terms (e.g., liver disease) that could lead to misclassification and overestimation of the prevalence of these conditions.

The completeness of recorded information may differ between databases. Information on medications can be considered complete in all databases as it is based on the automatic recording of prescriptions (THIN) or pharmacy dispensings (EpiChron cohort, SIDIAP, Sweden, and GePaRD). However, a first specialist prescription may be missed in GP databases (THIN and SIDIAP), which could overestimate discontinuation of cilostazol. Also, relevant over‐the‐counter medications, such as aspirin, are not recorded in any of the study data sources. Information on smoking was available in THIN and SIDIAP but for only 48% of users in the EpiChron cohort. Recording of diagnoses in THIN can be considered reliable; estimates of the prevalence of chronic and frequent disease are consistent with those reported in national health statistics in the UK (Blak *et al*., 2011). Recording of diagnoses for administrative hospital requirements (Sweden) or for insurance billing purposes (GePaRD) can also be considered reasonably complete. The lower prevalence of comorbidity in the EpiChron cohort than in SIDIAP (e.g., diabetes, 29.9 vs. 40.4% respectively; hypertension, 54.9 vs. 63.0%; hyperlipidemia, 37.4 vs. 48.5%) could be related to some underrecording of diagnoses in the EpiChron cohort. Conversely, the lower percentages of patients in the EpiChron cohort treated with antihypertensives (63.6 vs. 74.5%, SIDIAP), blood glucose‐lowering drugs (20.9 vs. 32.2%), and insulin (11.8 vs. 15.5%) suggest that these differences could be due to different characteristics of cilostazol users (e.g., more severe patients in SIDIAP) or to different patterns of use of health services, which are organized and managed at the regional level.

The frequency of on‐label prescribing of cilostazol varied between the study databases and was lower in Spain than in the other countries. This variability could reflect not only differences in the recording of diagnoses between databases but also differences in the prescribing patterns of each country or region. Evaluation of off‐label use was based on the absence of recorded diagnoses for intermittent claudication or peripheral arterial disease. Thus, the absence of recorded information does not exclude that the diagnosis may have occurred but may not have been recorded. This may have led to overestimating off‐label prescribing in these populations.

Conclusions {#pds4167-sec-0023}
===========

This study indicates that the prevalence of cilostazol use varied by country and was higher in Spain than in the UK, Sweden, and Germany, and in men than in women. Among cilostazol users, the high prevalences of risk factors, comorbidity, and concurrent use of medications including interacting drugs suggest that this is a vulnerable population at increased risk of complications and especially cardiovascular events.
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